Slide 1: Supriya Lifescience Ltd. Revised Investor Presentation
SUPRIYA LIFESCIENCE LTD. Creating true values that bind global health Date: May 21, 2022 To, BSE Limited . National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex Mumbai- 400 001 Bandra (E), Mumbai - 400 051 Scrip
Slide 2: Earnings Presentation Q4FY22
Earnings Presentation Q4FY22
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Supriya Lifescience Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Table of Contents
TABLE OF CONTENTS Sustainability 1. Q4 & FY22 Highlights Growth 2. Company Overview 3. Financial Performance Profitability 4. Future Outlook
Slide 5: Q4 & FY22 Highlights
Q4 & FY22 Highlights
Slide 6: CMD's Message
CMD’s Message “ We have ended the year on a strong note, delivering a Operating Revenue growth of 35% Y-o-Y and healthy EBITDA margins at 40% and PAT margin at 29%. Despite the fact that the world continues to face tremendous business challenges, we have generated consistent FY22 results. The focus
Slide 7: Q4 & FY22 Highlights
Q4 & FY22 Highlights (in INR mn) Revenue EBITDA PBT PAT * +37% +12% +15% -5% 1,812.7 Quarterly 752.2 754.8 485.1 462.1 671.7 656.4 1,321.1 Q4FY21 Q4FY22 Q4FY21 Q4FY22 Q4FY21 Q4FY22 Q4FY21 Q4FY22 Revenue EBITDA PBT PAT +35% +24% +24% +23% 5,300.5 2,139.8 2,072.4 1,518.1 Yearly 3,912.4 1,731.7 1,673.1
Slide 8: Business Mix Revenue Contribution – By Therapy
Business Mix Revenue Contribution – By Therapy Performance of the Therapeutic Areas FY19 2,104 FY20 FY21 FY22 1,189 909 1,012 1,113 710 775 611 598 533 617 567 474 396 433 198 197 205 206 277 266 128 192 164 (in INR mn) Analgesic/Anesthetic Anti-histamine Vitamins Anti-Asthmatic Anti-allergic Anti-m
Slide 9: Business Mix Revenue Contribution – By Region
Business Mix Revenue Contribution – By Region Regional Performance 61% Q4FY21 51% Q4FY22 30% 24% 13% 9% 4% 2% 3% 3% Asia Europe LAC North America Others 52% 51% FY21 FY22 30% 19% 16% 12% 8% 5% 3% 4% Asia Europe LAC North America Others 8 FY22 Q4 Earnings Presentation
Slide 10: Profit & Loss Statement
Profit & Loss Statement Particulars (in INR mn) Q4 FY22 Q4 FY21 Y-o-Y Q3 FY22 Q-o-Q FY22 FY21 Y-o-Y Revenue from Operations 1,812.7 1,321.1 37% 1,216.0 49% 5,300.5 3,912.4 35% Cost of Materials Consumed 382.4 415.0 722.3 1,988.3 1,405.7 Purchase of Traded Goods - - - - - Changes in Inventories of Fi
Slide 11: Company Overview
Company Overview
Slide 12: Business Overview
Business Overview Approved facility with Diversified operations Largest exporter of strong IP Niche product basket of Chlorpeniramine with presence in Maleate, Ketamine 38 APIs 86 countries Hydrochloride and Salbutamol Sulphate from India 14 DMFs with USFDA Manufacturing facility spread across React
Slide 13: Journey So Far
Journey So Far 2008 2009 2010 2011 2013 2014 Incorporation & Started CEP granted for IDL granted for COFEPRIS and USFDA approval conversion from production of Chlorphenamine Chlorphenamine KFDA granted; IDL a partnership Ketamine Maleate Maleate approval granted granted for firm to a public hydrochl
Slide 14: Company Differentiators
Company Differentiators Significant scale with leadership position across key & niche products Backward integrated business model Geographically diversified revenues with a global presence across 86 countries Advanced manufacturing and research and development capabilities Experienced senior managem
Slide 15: Significant Scale with Leadership Position In Key Products
Significant Scale with Leadership Position In Key Products Niche product offerings of 38 APIs with demonstrated ability to develop & scale-up production Leading exporter from India Presence for 10+ yrs in large & growing markets % share of exports from India (in terms of volume) Cetirizine Dihydroch
Slide 16: Backward Integrated Business Model
Backward Integrated Business Model Cost-competitive Supply Security Low Price Risk In-House Processes Structure Steady supply of Protection against Less Dependence On External Increasing margins essential raw materials market fluctuations Parties Integrated business model helped us grow revenue and
Slide 17: Diversified Geographic Presence
Diversified Geographic Presence Growth in Regulated Markets +16% 53% 34% 33% 34% FY19 FY20 FY21 FY22 Presence in 86+ Countries Across Globe 16 FY22 Q4 Earnings Presentation
Slide 18: Diversified Revenues with Extensive Global Presence
Diversified Revenues with Extensive Global Presence Significant export presence, with low dependence on a specific geography … with customer concentration Export sales, as a % of revenue from operations Share of top 10 customers, as a % of revenue from operations 77.0% 76.0% 47% 71.0% 72.0% 40% 30%
Slide 19: Advanced Manufacturing and R&D Capabilities
Advanced Manufacturing and R&D Capabilities 4 7 547 KL 23,806 sq.mt. Manufacturing blocks Clean Reactor Land segregated therapy wise rooms capacity area ✓ Well delineated areas for R&D, quality control Scaled up Manufacturing Facilities over the years Steady improvement in capacity utilization (chem
Slide 20: R&D Capabilities
R&D Capabilities Supported by R&D driven mindset 14* DMFs 3* Process Patent DSIR approved 8* Filed in India facility CEPs ✓ The Company has a DSIR approved R&D facility in Parshuram Lote, Maharashtra. ✓ Team of 26 scientists* primarily focused across the value chain of API process development ✓ Supr
Slide 21: Complex Chemistries & Reaction
Complex Chemistries & Reaction Focus on uniform manufacturing standards to achieve standardised product quality across markets High vacuum distillations … across varied class of reactions Ability to handle complex chemistries.. Cyclisation Grignard reaction ✓ Simple to highly complex chiral centre m
Slide 22: Recognized by Key Regulatory Bodies
Recognized by Key Regulatory Bodies 21 FY22 Q4 Earnings Presentation
Slide 23: Number of API's Under Pipeline
Number of API’s Under Pipeline API’s Under Pipeline Status USDMF’s 6 API’s Submitted CEP 2 API’s Granted USDMF 1 API Submission Under Progress CEP 2 API’s Assessment Under Progress CEP 2 API’s Submission Under Progress Note : New API’s in Anti-diabetic and central nervous system therapies 22 FY22 Q4
Slide 24: Macroeconomic Factors Influencing Supriya Lifescience
Macroeconomic Factors Influencing Supriya Lifescience Russia – Ukraine China plants shutdown Regulatory and Cause COVID 19 War due to pollution customer audits › Increase in cost of raw › Delay in raw material supplies › More stringent audits Effect › Delay in export shipments › Increase in cost of
Slide 25: Awards & Accreditation
Awards & Accreditation 2009 2010 2016 2017 2019 Certificate of Excellence for Special Recognition National Award Export House for the Year for Export House for the Year for Outstanding Export outstanding Export Performance in for Research and Development 2015-16 awarded by Directorate of 2016-17 awa
Slide 26: Key Management Team
Key Management Team Satish Wagh Saloni Wagh Shivani Wagh Shireesh Ambhaikar Ashish Nayak Chairman & MD Whole-time Director Whole-time Director Chief Executive Officer Chief Financial Officer • B.Sc. from R.D National College and • B.Sc. from Parle Tilak Vidhyalaya • Bachelor’s degree in management •
Slide 27: Corporate Social Responsibilities
Corporate Social Responsibilities Invested Rs. 223.05 lakhs in CSR initiatives in F.Y. 2021- 2022 including amount outlay for the ongoing project. Covid-19 support: Supported the underprivileged community and police departments in Khed and Ratnagiri (Maharashtra) during the global pandemic, distribu
Slide 28: Quality Week
Quality Week Quality is the core of our complete operations . Our vision is to globalize, harmonize and simplify GMP processes to ensure a sustainable quality culture. In alignment with this vision , We at Supriya Lifescience Ltd. celebrated Quality Week from 25th Jan to 29th Jan 2022. The Purpose o
Slide 29: Financial Performance
Financial Performance
Slide 30: Consistent & Strong Financial Performance
Consistent & Strong Financial Performance Robust revenue growth … Capex Spend … and, focus on profitability EBITDA +23.7% 5,300.5 949 PAT +47.3% 2,140 3,911.9 1,732 3,195.4 1,518 2,801.0 1,236 1,063 670 734 179 394 53 94 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 Return on Net Worth
Slide 31: Working Capital Break-up
Working Capital Break-up No of days Inventory Receivables Payables 206 73 78 79 68 75 172 63 53 130 49 76 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 Net Working Capital Reasons of RM Inventory levels higher than normal 194 196 Shutdown of plants in China due to pollution related iss
Slide 32: Summary Statement of Profit and Loss
Summary Statement of Profit and Loss Particulars (in INR mn) FY22 FY21 FY20 FY19 Total Revenue 5,300.5 3,912.4 3,195.4 2,801.0 Cost of Materials Consumed 1,988.3 1,405.7 1,523.8 1,460.7 Purchase of Traded Goods - - - - Changes in Inventories of Finished Goods and Work in Progress -30.3 -124.5 -139.0
Slide 33: Summary Statement of Assets and Liabilities
Summary Statement of Assets and Liabilities Particulars (in INR mn) Mar 22 Mar 21 Particulars (in INR mn) Mar 22 Mar 21 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY (i) Property, plant and equipment 1824.7 969.5 (i) Equity share capital 161.0 146.4 (ii) Right to Use Asset 58.0 14.7 (ii) O
Slide 34: Summary statement of Cashflow
Summary statement of Cashflow (in INR mn) Particulars (in INR mn) FY22 FY21 FY20 FY19 Cash Flow from Operating Activities Profit before Tax 2,072.4 1,673.9 962.3 571.0 Adjustment for Non-Operating Items 68.7 53.1 102.4 124.6 Operating Profit before Working Capital Changes 2,141.2 1,727.0 1,064.7 695
Slide 35: Future Outlook
Future Outlook
Slide 36: Future Outlook
Future Outlook Two new R&D centres • The future of company lies in R&D, initiated the process of setting up enhanced R&D facility 1. At Lote Parshuram to cater to lifecycle management and further backward integration projects (to be operational by Q2FY23) 2. At Ambernath to cater to new molecules an
Slide 37: Future Outlook
Future Outlook CMO/CDMO space • Company understands large scale special chemical manufacturing and has experience in handling hazardous complex process chemistry. • Initiated discussion with various companies ranging from big pharma to innovator companies to work as a partner for supplying products
Slide 38: Glossary
Glossary • API – Active Pharmaceutical Intermediates • DMF – Drug Master File • CEP – Certificate of Sustainability • USFDA – US Food And Drug Administration • EDQM – European Directorate for the Quality of Medicines & HealthCare • IDL – Import Drug Licence of China • KFDA – Korea Medical Device Reg
Slide 39: Thank You!
Thank You! Company : Investor Relations Advisors : Orient Capital (a division of Link Group) Supriya Lifescience Limited Mr. Rajesh Agrawal CIN: L51900MH2008PLC180452 +91 99674 91495 rajesh.agrawal@linkintime.co.in Mr. Ashish Nayak – Chief Financial Officer cfo@supriyalifescience.com Ms. Rasika Sawa